Molecular and therapeutic aspects of varicella-zoster virus infection

Expert Reviews in Molecular Medicine

Volumn 7, Issue 15, 2005, Pages 1-24

  Quinlivan, Mark ^a   Breuer, Judith ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Assembly; Ganglia; Oka vaccine; PBMCs; Tropism; Varicella zoster virus

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; CHICKENPOX VACCINE; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; MEASLES MUMPS RUBELLA VACCINE; NUCLEOSIDE ANALOG; PENCICLOVIR; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

CHICKENPOX; HERPES VIRUS; HERPES ZOSTER; HOST RANGE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; SENSORY NERVE CELL; SKIN CELL; SPECIES DIFFERENCE; VARICELLA ZOSTER VIRUS; VIROGENESIS; VIRUS PATHOGENESIS; VIRUS REACTIVATION;

ANIMALS; ANTIVIRAL AGENTS; CHICKENPOX; CHICKENPOX VACCINE; DNA REPLICATION; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; PHENOTYPE; VIRUS LATENCY;

ANIMALIA; HERPES ZOSTER; HERPESVIRIDAE; HUMAN HERPESVIRUS 3; SIMPLEXVIRUS;

EID: 33645937961     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S146239940500966X     Document Type: Review

References (195)

1. Roizmann, B. et al. (1992) The family Herpesviridae: An update. The Herpesvirus Study Group of the International Committee on Taxonomy of Viruses. Arch Virol 123, 425-449, PubMed: 1562239
2. Brunell, P.A. (1989) Transmission of chickenpox in a school setting prior to the observed exanthem. Am J Dis Child 143, 1451-1452, PubMed: 2556025
3. Tsolia, M. et al. (1990) Live attenuated varicella vaccine: Evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr 116, 184-189, PubMed: 2153790
4. Arvin, A.M., Moffat, J.F. and Redman, R. (1996) Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Adv Virus Res 46, 263-309, PubMed: 8824702
5. Ku, C.C. et al. (2004) Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med 200, 917-925, PubMed: 15452178
6. Miller, E., Marshall, R. and Vurden, J. (1993) Epidemiology, outcome and control of varicella zoster infection. Rev Med Microbiol 222-230, PubMed: 10328533
7. Hawrami, K., Breuer, J. (1999). Development of a flurogenic polymerase chain reaction assay (TaqMan) for the detection and quantitation of varicella zoster virus. J. Virological. Methods 79, 33-40, PubMed: 10328533
8. Mainka, C. et al. (1998) Characterization of viremia at different stages of varicella-zoster virus infection. J Med Virol 56, 91-98, PubMed: 9700639
9. Schunemann, S., Mainka, C. and Wolff, M.H. (1998) Subclinical reactivation of varicella-zoster virus in immunocompromised and immunocompetent individuals. Intervirology 41, 98-102, PubMed: 9820843
10. Hope-Simpson, R.E. (1965) The Nature of Herpes Zoster: A Long-Term Study and a New Hypothesis. Proc R Soc Med 58, 9-20, PubMed: 14267505
11. Buchbinder, S.P. et al. (1992) Herpes zoster and human immunodeficiency virus infection. J Infect Dis 166, 1153-1156, PubMed: 1308664
12. Kleinschmidt-DeMasters, B.K. and Gilden, D.H. (2001) Varicella-Zoster virus infections of the nervous system: Clinical and pathologic correlates. Arch Pathol Lab Med 125, 770-780, PubMed: 11371229
13. Scott, F.T. et al. (2003) A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 70 Suppl 1, S24-30, PubMed: 12627483
14. Davison, A.J. and Scott, J.E. (1986) The complete DNA sequence of varicella-zoster virus. J Gen Virol 67 (Pt 9), 1759-1816, PubMed: 3018124
15. Gomi, Y. et al. (2002) Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 76, 11447-11459, PubMed: 12388706
16. Grose, C. et al. (2004) Complete DNA sequence analyses of the first two varicella-zoster virus glycoprotein E (D150N) mutant viruses found in North America: Evolution of genotypes with an accelerated cell spread phenotype. J Virol 78, 6799-6807, PubMed: 15194755
17. Arvin, A.M. (1996) Varicella-zoster virus. In Virology (Fields, B.N. et al., eds), pp. 2547-2586, Lippincott-Raven Publishers, Philadelphia, PA, USA
18. Ku, C.C. et al. (2002) Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol 76, 11425-11433, PubMed: 12388703
19. Moffat, J.F. et al. (1995) Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol 69, 5236-5242, PubMed: 7636965
20. Cole, N.L. and Grose, C. (2003) Membrane fusion mediated by herpesvirus glycoproteins: The paradigm of varicella-zoster virus. Rev Med Virol 13, 207-222, PubMed: 12820183
21. Jacquet, A. et al. (1998) The varicella zoster virus glycoprotein B (gB) plays a role in virus binding to cell surface heparan sulfate proteoglycans. Virus Res 53, 197-207, PubMed: 9620211
22. Rodriguez, J.E., Moninger, T. and Grose, C. (1993) Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. Virology 196, 840-844, PubMed: 8396811
23. Cohen, J.I. and Nguyen, H. (1997) Varicella-zoster virus glycoprotein I is essential for growth of virus in Vero cells. J Virol 71, 6913-6920, PubMed: 9261418
24. Montalvo, E.A. and Grose, C. (1987) Assembly and processing of the disulfide-linked varicella-zoster virus glycoprotein gpII(140). J Virol 61, 2877-2884, PubMed: 3039175
25. Wang, Z.H. et al. (2000) Trafficking of varicella-zoster virus glycoprotein gI: T(338)-dependent retention in the trans-Golgi network, secretion, and mannose 6-phosphate-inhibitable uptake of the ectodomain. J Virol 74, 6600-6613, PubMed: 10864674
26. Gershon, A.A. et al. (1994) Intracellular transport of newly synthesized varicella-zoster virus: Final envelopment in the trans-Golgi network. J Virol 68, 6372-6390, PubMed: 8083976
27. Zhu, Z. et al. (1995) Envelopment of varicella-zoster virus: Targeting of viral glycoproteins to the trans-Golgi network. J Virol 69, 7951-7959, PubMed: 7494308
28. Kinchington, P.R. et al. (1986) Putative glycoprotein gene of varicella-zoster virus with variable copy numbers of a 42-base-pair repeat sequence has homology to herpes simplex virus glycoprotein C. J Virol 59, 660-668, PubMed: 3016329
29. Inchauspe, G., Nagpal, S. and Ostrove, J.M. (1989) Mapping of two varicella-zoster virus-encoded genes that activate the expression of viral early and late genes. Virology 173, 700-709, PubMed: 2556848
30. Kinchington, P.R. et al. (1992) The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J Virol 66, 359-366, PubMed: 1309252
31. Kinchington, P.R., Fite, K. and Turse, S.E. (2000) Nuclear accumulation of IE62, the varicella-zoster virus (VZV) major transcriptional regulatory protein, is inhibited by phosphorylation mediated by the VZV open reading frame 66 protein kinase. J Virol 74, 2265-2277, PubMed: 10666257
32. Moriuchi, M. et al. (1994) Varicella-zoster virus (VZV) virion-associated transactivator open reading frame 62 protein enhances the infectivity of VZV DNA. Virology 200, 297-300, PubMed: 8128631
33. Perera, L.P. et al. (1992) Regulation of varicella-zoster virus gene expression in human T lymphocytes. J Virol 66, 5298-5304, PubMed: 1323696
34. Spengler, M. et al. (2001) Interactions among structural proteins of varicella zoster virus. Arch Virol Suppl 71-79, PubMed: 11339553
35. Sato, H. et al. (2002) Varicella-zoster virus (VZV) ORF17 protein induces RNA cleavage and is critical for replication of VZV at 37 degrees C but not 33 degrees C. J Virol 76, 11012-11023, PubMed: 12368344
36. Ruyechan, W.T. and Hay, J. (2000) DNA replication. In Varicella-Zoster Virus and Clinical Management (Arvin, A.M. and Gershon, A.A., eds), pp. 51-73, Cambridge University Press, Cambridge, UK
37. Mocarski, E.S. and Roizman, B. (1982) Structure and role of the herpes simplex virus DNA termini in inversion, circularization and generation of virion DNA. Cell 31, 89-97, PubMed: 6297756
38. Davison, A.J. (1984) Structure of the genome termini of varicella-zoster virus. J Gen Virol 65 (Pt 11), 1969-1977, PubMed: 6094711
39. Stow, N.D., Weir, H.M. and Stow, E.C. (1990) Analysis of the binding sites for the varicella-zoster virus gene 51 product within the viral origin of DNA replication. Virology 177, 570-577, PubMed: 2164726
40. Chen, D. and Olivo, P.D. (1994) Expression of the varicella-zoster virus origin-binding protein and analysis of its site-specific DNA-binding properties. J Virol 68, 3841-3849, PubMed: 8189521
41. Kinchington, P.R. et al. (1988) Identification and characterization of a varicella-zoster virus DNA-binding protein by using antisera directed against a predicted synthetic oligopeptide. J Virol 62, 802-809, PubMed: 2828675
42. Jacob, R.J., Morse, L.S. and Roizman, B. (1979) Anatomy of herpes simplex virus DNA. XII. Accumulation of head-to-tail concatemers in nuclei of infected cells and their role in the generation of the four isomeric arrangements of viral DNA. J Virol 29, 448-457, PubMed: 219240
43. Wang, Z.H. et al. (2001) Essential role played by the C-terminal domain of glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: Interactions of glycoproteins with tegument. J Virol 75, 323-340, PubMed: 11119602
44. Harson, R. and Grose, C. (1995) Egress of varicella-zoster virus from the melanoma cell: A tropism for the melanocyte. J Virol 69, 4994-5010, PubMed: 7609070
45. Gabel, C.A. et al. (1989) Varicella-zoster virus glycoprotein oligosaccharides are phosphorylated during posttranslational maturation. J Virol 63, 4264-4276, PubMed: 2550667
46. Zhu, Z. et al. (1996) Targeting of glycoprotein I (gE) of varicella-zoster virus to the trans-Golgi network by an AYRV sequence and an acidic amino acid-rich patch in the cytosolic domain of the molecule. J Virol 70, 6563-6575, PubMed: 8794291
47. Heineman, T.C., Krudwig, N. and Hall, S.L. (2000) Cytoplasmic domain signal sequences that mediate transport of varicella-zoster virus gB from the endoplasmic reticulum to the Golgi. J Virol 74, 9421-9430, PubMed: 11000211
48. Wang, Z. et al. (1998) Intracellular transport of varicella-zoster glycoproteins. J Infect Dis 178 Suppl 1, S7-12, PubMed: 9852965
49. Duus, K.M. and Grose, C. (1996) Multiple regulatory effects of varicella-zoster virus (VZV) gL on trafficking patterns and fusogenic properties of VZV gH. J Virol 70, 8961-8971, PubMed: 8971025
50. Gershon, M.D. and Gershon, A.A. (1999) Role of glycoproteins in varicella-zoster virus infection. Contrib Microbiol 3, 43-60, PubMed: 10599520
51. Alconada, A. et al. (1998) Intracellular transport of the glycoproteins gE and gI of the varicella-zoster virus. gE accelerates the maturation of gI and determines its accumulation in the trans-Golgi network. J Biol Chem 273, 13430-13436, PubMed: 9593675
52. Kenyon, T.K., Cohen, J.I. and Grose, C. (2002) Phosphorylation by the varicella-zoster virus ORF47 protein serine kinase determines whether endocytosed viral gE traffics to the trans-Golgi network or recycles to the cell membrane. J Virol 76, 10980-10993, PubMed: 12368341
53. Heineman, T.C. and Hall, S.L. (2002) Role of the varicella-zoster virus gB cytoplasmic domain in gB transport and viral egress. J Virol 76, 591-599, PubMed: 11752150
54. Duus, K.M., Hatfield, C. and Grose, C. (1995) Cell surface expression and fusion by the varicella-zoster virus gH:gL glycoprotein complex: analysis by laser scanning confocal microscopy. Virology 210, 429-440, PubMed: 7618278
55. Pasieka, T.J., Maresova, L. and Grose, C. (2003) A functional YNKI motif in the short cytoplasmic tail of varicella-zoster virus glycoprotein gH mediates clathrin-dependent and antibody-independent endocytosis. J Virol 77, 4191-4204, PubMed: 12634377
56. Olson, J.K. and Grose, C. (1998) Complex formation facilitates endocytosis of the varicella-zoster virus gE:gI Fc receptor. J Virol 72, 1542-1551, PubMed: 9445058
57. Kimura, H., Straus, S.E. and Williams, R.K. (1997) Varicella-zoster virus glycoproteins E and I expressed in insect cells form a heterodimer that requires the N-terminal domain of glycoprotein I. Virology 233, 382-391, PubMed: 9217061
58. Litwin, V., Sandor, M. and Grose, C. (1990) Cell surface expression of the varicella-zoster virus glycoproteins and Fc receptor. Virology 178, 263-272, PubMed: 2167554
59. Litwin, V., Jackson, W. and Grose, C. (1992) Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI. J Virol 66, 3643-3651, PubMed: 1316474
60. Mallory, S., Sommer, M. and Arvin, A.M. (1997) Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking. J Virol 71, 8279-8288, PubMed: 9343180
61. Mettenleiter, T.C. (2002) Herpesvirus assembly and egress. J Virol 76, 1537-1547, PubMed: 11799148
62. Dahms, N.M., Lobel, P. and Kornfeld, S. (1989) Mannose 6-phosphate receptors and lysosomal enzyme targeting. J Biol Chem 264, 12115-12118, PubMed: 2545698
63. Westlund, B., Dahms, N.M. and Kornfeld, S. (1991) The bovine mannose 6-phosphate/insulin-like growth factor II receptor. Localization of mannose 6-phosphate binding sites to domains 1-3 and 7-11 of the extracytoplasmic region. J Biol Chem 266, 23233-23239, PubMed: 1660469
64. Brunetti, C.R. et al. (1998) Herpes simplex virus gD and virions accumulate in endosomes by mannose 6-phosphate-dependent and - independent mechanisms. J Virol 72, 3330-3339, PubMed: 9525660
65. Griffiths, G. et al. (1988) The mannose 6-phosphate receptor and the biogenesis of lysosomes. Cell 52, 329-341, PubMed: 2964276
66. Gershon, A., Cosio, L. and Brunell, P.A. (1973) Observations on the growth of varicella-zoster virus in human diploid cells. J Gen Virol 18, 21-31, PubMed: 4354535
67. Chen, J.J. et al. (2004) Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell 119, 915-926, PubMed: 15620351
68. Jones, F. and Grose, C. (1988) Role of cytoplasmic vacuoles in varicella-zoster virus glycoprotein trafficking and virion envelopment. J Virol 62, 2701-2711, PubMed: 2839696
69. Padilla, J.A., Nii, S. and Grose, C. (2003) Imaging of the varicella zoster virion in the viral highways: Comparison with herpes simplex viruses 1 and 2, cytomegalovirus, pseudorabies virus, and human herpes viruses 6 and 7. J Med Virol 70 Suppl 1, S103-110, PubMed: 12627497
70. Maresova, L., Pasieka, T.J. and Grose, C. (2001) Varicella-zoster Virus gB and gE coexpression, but not gB or gE alone, leads to abundant fusion and syncytium formation equivalent to those from gH and gL coexpression. J Virol 75, 9483-9492, PubMed: 11533210
71. Santos, R.A. et al. (2000) Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology 275, 306-317, PubMed: 10998331
72. Mo, C., Schneeberger, E.E. and Arvin, A.M. (2000) Glycoprotein E of varicella-zoster virus enhances cell-cell contact in polarized epithelial cells. J Virol 74, 11377-11387, PubMed: 11070038
73. Kennedy, P.G. et al. (2001) Varicella-Zoster virus gene expression in latently infected rat dorsal root ganglia. Virology 289, 218-223, PubMed: 11689044
74. Sato, H., Pesnicak, L. and Cohen, J.I. (2003) Use of a rodent model to show that varicella-zoster virus ORF61 is dispensable for establishment of latency. J Med Virol 70 Suppl 1, S79-81, PubMed: 12627493
75. Grinfeld, E., Sadzot-Delvaux, C. and Kennedy, P.G. (2004) Varicella-Zoster virus proteins encoded by open reading frames 14 and 67 are both dispensable for the establishment of latency in a rat model. Virology 323, 85-90, PubMed: 15165821
76. Mahalingam, R. et al. (1990) Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia. N Engl J Med 323, 627-631, PubMed: 2166914
77. Cohrs, R.J. et al. (1995) Varicella-zoster virus (VZV) transcription during latency in human ganglia: Prevalence of VZV gene 21 transcripts in latently infected human ganglia. J Virol 69, 2674-2678, PubMed: 7884921
78. Gilden, D.H. et al. (1983) Varicella-zoster virus DNA in human sensory ganglia. Nature 306, 478-480, PubMed: 6316159
79. Pavan-Langston, D. and Dunkel, E.C. (1989) Ocular varicella-zoster virus infection in the guinea pig. A new in vivo model. Arch Ophthalmol 107, 1068-1072, PubMed: 2546523
80. Clarke, P. et al. (1995) Configuration of latent varicella-zoster virus DNA. J Virol 69, 8151-8154, PubMed: 7494340
81. Cohrs, R.J., Barbour, M. and Gilden, D.H. (1996) Varicella-zoster virus (VZV) transcription during latency in human ganglia: Detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J Virol 70, 2789-2796, PubMed: 8627753
82. Kennedy, P.G., Grinfeld, E. and Gow, J.W. (1998) Latent varicella-zoster virus is located predominantly in neurons in human trigeminal ganglia. Proc Natl Acad Sci U S A 95, 4658-4662, PubMed: 9539794
83. Lungu, O. et al. (1998) Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during latency. Proc Natl Acad Sci U S A 95, 7080-7085, PubMed: 9618542
84. Kennedy, P.G., Grinfeld, E. and Bell, J.E. (2000) Varicella-zoster virus gene expression in latently infected and explanted human ganglia. J Virol 74, 11893-11898, PubMed: 11090189
85. Cohrs, R.J. et al. (2003) Varicella-zoster virus gene 66 transcription and translation in latently infected human Ganglia. J Virol 77, 6660-6665, PubMed: 12767985
86. Grinfeld, E. and Kennedy, P.G. (2004) Translation of varicella-zoster virus genes during human ganglionic latency. Virus Genes 29, 317-319, PubMed: 15550771
87. Kennedy, P.G., Grinfeld, E. and Gow, J.W. (1999) Latent Varicella-zoster virus in human dorsal root ganglia. Virology 258, 451-454, PubMed: 10366583
88. Mahalingam, R. et al. (1993) Quantitation of latent varicella-zoster virus DNA in human trigeminal ganglia by polymerase chain reaction. J Virol 67, 2381-2384, PubMed: 8383249
89. LaGuardia, J.J., Cohrs, R.J. and Gilden, D.H. (1999) Prevalence of varicella-zoster virus DNA in dissociated human trigeminal ganglion neurons and nonneuronal cells. J Virol 73, 8571-8577, PubMed: 10482610
90. Pevenstein, S.R. et al. (1999) Quantitation of latent varicella-zoster virus and herpes simplex virus genomes in human trigeminal ganglia. J Virol 73, 10514-10518, PubMed: 10559370
91. Cohrs, R.J. et al. (2000) Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR. J Virol 74, 11464-11471, PubMed: 11090142
92. Levin, M.J. et al. (2003) Varicella-zoster virus DNA in cells isolated from human trigeminal ganglia. J Virol 77, 6979-6987, PubMed: 12768016
93. Gilden, D.H. et al. (1987) Detection of varicella-zoster virus nucleic acid in neurons of normal human thoracic ganglia. Ann Neurol 22, 377-380, PubMed: 2823688
94. Lungu, O. et al. (1995) Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A 92, 10980-10984, PubMed: 7479921
95. Croen, K.D. et al. (1988) Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses. Proc Natl Acad Sci U S A 85, 9773-9777, PubMed: 2849116
96. Takahashi, M. et al. (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2, 1288-1290, PubMed: 4139526
97. Singhvi, R. et al. (1996) Assessment of virus infection in cultured cells using metabolic monitoring. Cytotechnology 79-85, PubMed: 3014478
98. D'Hondt, E., Berge, E., Colinet, G., Duchene, M., Peetermans, J. (1985). Production and quality control of the Oka-strain live varicella vaccine. Postgrad. Med. J. 61(Suppl 4), 53-56, PubMed
99. Breuer, J. (2003) Live attenuated vaccine for the prevention of varicella-zoster virus infection: Does it work, is it safe and do we really need it in the UK? J Med Microbiol 52, 1-3, PubMed: 12488559
100. Giller, R.H., Winistorfer, S. and Grose, C. (1989) Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J Infect Dis 160, 919-928, PubMed: 2555419
101. Brisson, M., Edmunds, W.J. and Gay, N.J. (2003) Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 70 Suppl 1, S31-37, PubMed: 12627484
102. Oxman, M.N. (1995) Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 45, S41-46, PubMed: 8545018
103. Asano, Y. et al. (1994) Experience and reason: Twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 94, 524-526, PubMed: 7936864
104. Ampofo, K. et al. (2002) Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis 34, 774-779, PubMed: 11830801
105. Gershon, A.A. (2002) Varicella vaccine - are two doses better than one? N Engl J Med 347, 1962-1963, PubMed: 12477947
106. Sharrar, R.G. et al. (2000) The postmarketing safety profile of varicella vaccine. Vaccine 19, 916-923, PubMed: 11115716
107. Moffat, J.F. et al. (1998) Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol 72, 965-974, PubMed: 9444989
108. Soong, W. et al. (2000) Infection of human T lymphocytes with varicella-zoster virus: An analysis with viral mutants and clinical isolates. J Virol 74, 1864-1870, PubMed: 10644359
109. Somekh, E. and Levin, M.J. (1993) Infection of human fetal dorsal root neurons with wild type varicella virus and the Oka strain varicella vaccine. J Med Virol 40, 241-243, PubMed: 8394874
110. Weibel, R.E. et al. (1984) Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med 310, 1409-1415, PubMed: 6325909
111. Gomi, Y. et al. (2000) Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity. J Med Virol 61, 497-503, PubMed: 10897069
112. Gomi, Y. et al. (2001) Comparison of DNA sequence and transactivation activity of open reading frame 62 of Oka varicella vaccine and its parental viruses. Arch Virol Suppl 49-56, PubMed: 11339550
113. Quinlivan, M.L. et al. (2004) Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus. J Infect Dis 190, 793-796, PubMed: 15272408
114. Wagenaar, T.R. et al. (2003) The out of Africa model of varicella-zoster virus evolution: Single nucleotide polymorphisms and private alleles distinguish Asian clades from European/North American clades. Vaccine 21, 1072-1081, PubMed: 12559782
115. Zerboni, L. et al. (2005) Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology 332, 337-346, PubMed: 15661165
116. Harper, D.R., Gilbert, R.L. and Jeffries, D.J. (1998) Molecular biology of varicella-zoster virus. A review prepared for the UK Advisory Group on Chickenpox. J Infect 36 Suppl 1, 1-10, PubMed: 9514102
117. Naesens, L. and De Clercq, E. (2001) Recent developments in herpesvirus therapy. Herpes 8, 12-16, PubMed: 11867011
118. Kimberlin, D.W. and Whitley, R.J. (1996) Antiviral resistance: mechanisms, clinical significance, and future implications. J Antimicrob Chemother 37, 403-421, PubMed: 9182098
119. Gilbert, C., Bestman-Smith, J. and Boivin, G. (2002) Resistance of herpesviruses to antiviral drugs: Clinical impacts and molecular mechanisms. Drug Resist Updat 5, 88-114, PubMed: 12135584
120. Villarreal, E.C. (2001) Current and potential therapies for the treatment of herpesvirus infections. Prog Drug Res Spec No, 185-228, PubMed: 11548208
121. Snoeck, R. et al. (1994) Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient. J Med Virol 42, 338-347, PubMed: 8046424
122. Talarico, C.L., Phelps, W.C. and Biron, K.K. (1993) Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol 67, 1024-1033, PubMed: 8380452
123. Visse, B. et al. (1998) Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect Dis 178 Suppl 1, S55-57, PubMed: 9852975
124. Fillet, A.M. et al. (1995) Foscarnet-resistant multidermatomal zoster in a patient with AIDS. Clin Infect Dis 21, 1348-1349, PubMed: 8589182
125. Visse, B., Huraux, J.M. and Fillet, A.M. (1999) Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. J Med Virol 59, 84-90, PubMed: 10440813
126. Balzarini, J. and McGuigan, C. (2002) Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides. Biochim Biophys Acta 1587, 287-295, PubMed: 12084470
127. Visalli, R.J. et al. (2003) Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. J Virol 77, 2349-2358, PubMed: 12551972
128. Abendroth, A. and Arvin, A.M. (2001) Immune evasion as a pathogenic mechanism of varicella zoster virus. Semin Immunol 13, 27-39, PubMed: 11289797
129. Huang, Z. et al. (1992) Specific lysis of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones. J Virol 66, 2664-2669, PubMed: 1348545
130. Sharp, M. et al. (1992) Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis 165, 852-858, PubMed: 1314871
131. Arvin, A.M. et al. (1986) Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol 137, 1346-1351, PubMed: 3016094
132. Hayward, A.R. (1990) T-cell responses to predicted amphipathic peptides of varicella-zoster virus glycoproteins II and IV. J Virol 64, 651-655, PubMed: 2153231
133. Bergen, R.E. et al. (1991) Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus. Viral Immunol 4, 151-166, PubMed: 1725699
134. Frey, C.R. et al. (2003) Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis 188, 40-52, PubMed: 12825169
135. Sadzot-Delvaux, C., Arvin, A.M. and Rentier, B. (1998) Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity. J Infect Dis 178 Suppl 1, S43-47, PubMed: 9852972
136. Arvin, A.M. et al. (2002) Memory cytotoxic T cell responses to viral tegument and regulatory proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster virus. Viral Immunol 15, 507-516, PubMed: 12479399
137. Asano, Y. et al. (1985) Viral replication and immunologic responses in children naturally infected with varicella-zoster virus and in varicella vaccine recipients. J Infect Dis 152, 863-868, PubMed: 2995510
138. Arvin, A.M. et al. (1986) Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis 154, 422-429, PubMed: 3016110
139. Feldman, S. and Lott, L. (1987) Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics 80, 465-472, PubMed: 2821476
140. Reis, A.D., Pannuti, C.S. and de Souza, V.A. (2003) [Prevalence of varicella-zoster virus antibodies in young adults from different Brazilian climatic regions]. Rev Soc Bras Med Trop 36, 317-320, PubMed: 12908030
141. Martin, K.A. et al. (1994) Occurrence of chickenpox during pregnancy in women seropositive for varicella-zoster virus. J Infect Dis 170, 991-995, PubMed: 7930746
142. Koskiniemi, M. et al. (2002) Acute central nervous system complications in varicella zoster virus infections. J Clin Virol 25, 293-301, PubMed: 12423693
143. van Loon, A.M. et al. (1992) Antibody-capture enzyme-linked immunosorbent assays that use enzyme-labelled antigen for detection of virus-specific immunoglobulin M, A and G in patients with varicella or herpes zoster. Epidemiol Infect 108, 165-174, PubMed: 1312479
144. Terada, K. et al. (2002) Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated varicella vaccine. Vaccine 20, 3638-3643, PubMed: 12399190
145. Schmidt, M. et al. (2003) Varicella-zoster virus isolates, but not the vaccine strain OKA, induce sensitivity to alpha-1 and beta-1 adrenergic stimulation of sensory neurones in culture. J Med Virol 70 Suppl 1, S82-89, PubMed: 12627494
146. Palumbo, P.E. et al. (1984) Investigation of varicella-zoster virus-infected cell proteins that elicit antibody production during primary varicella using the immune transfer method. J Gen Virol 65 (Pt 12), 2141-2147, PubMed: 6096492
147. Krah, D.L., Provost, P.J. and Ellis, R.W. (1995) Combined use of complement and anti-immunoglobulin in an enhanced neutralization assay for antibodies to varicella-zoster virus. J Virol Methods 53, 176-187, PubMed: 7673386
148. Grose, C., Edmond, B.J. and Brunell, P.A. (1979) Complement-enhanced neutralizing antibody response to varicella-zoster virus. J Infect Dis 139, 432-437, PubMed: 220336
149. Ihara, T. et al. (1991) Antibody response determined with antibody-dependent cell-mediated cytotoxicity (ADCC), neutralizing antibody, and varicella skin test in children with natural varicella and after varicella immunization. Acta Paediatr Jpn 33, 43-49, PubMed: 1649540
150. Arvin, A. (1987) Clinical manifestations of varicella and herpes zoster and the immune response to varicella zoster virus. In The Natural History of Varicella-zoster Virus (Hyman, R., ed.), pp. 67-130, CRC Press, New York, USA
151. Camitta, B. et al. (1994) Use of irradiated lymphocytes from immune donors for treatment of disseminated varicella. J Pediatr 124, 593-596, PubMed: 8151475
152. Kavaliotis, J. et al. (1998) Outbreak of varicella in a pediatric oncology unit. Med Pediatr Oncol 31, 166-169, PubMed: 9722899
153. Reimer, P. et al. (2003) Cellular and humoral immune reconstitution after autologous peripheral blood stem cell transplantation (PBSCT). Ann Hematol 82, 263-270, PubMed: 12739062
154. Dahl, H., Marcoccia, J. and Linde, A. (1997) Antigen detection: The method of choice in comparison with virus isolation and serology for laboratory diagnosis of herpes zoster in human immunodeficiency virus-infected patients. J Clin Microbiol 35, 347-349, PubMed: 9003593
155. Webster, A. et al. (1989) Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster. J Med Virol 27, 117-119, PubMed: 2537881
156. Offidani, M. et al. (2001) A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation. Clin Infect Dis 32, 1414-1422, PubMed: 11317241
157. Morrow, G. et al. (2003) Varicella-zoster virus productively infects mature dendritic cells and alters their immune function. J Virol 77, 4950-4959, PubMed: 12663800
158. Abendroth, A. et al. (2000) Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J Virol 74, 1900-1907, PubMed: 10644363
159. Abendroth, A. et al. (2001) Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol 75, 4878-4888, PubMed: 11312359
160. Konig, A. et al. (2003) The varicella-zoster virus induces apoptosis in vitro in subpopulations of primary human peripheral blood mononuclear cells. Microbes Infect 5, 879-889, PubMed: 12919856
161. Hood, C. et al. (2003) Varicella-zoster virus-infected human sensory neurons are resistant to apoptosis, yet human foreskin fibroblasts are susceptible: Evidence for a cell-type-specific apoptotic response. J Virol 77, 12852-12864, PubMed: 14610206
162. Baiker, A. et al. (2004) Varicella-zoster virus infection of human neural cells in vivo. Proc Natl Acad Sci U S A 101, 10792-10797, PubMed: 15247414
163. Chen, J.J. et al. (2003) Latent and lytic infection of isolated guinea pig enteric ganglia by varicella zoster virus. J Med Virol 70 Suppl 1, S71-78, PubMed: 12627492
164. Dalziel, R.G. et al. (2004) Allodynia in rats infected with varicella zoster virus - a small animal model for post-herpetic neuralgia. Brain Res Brain Res Rev 46, 234-242, PubMed: 15464211
165. Nagaike, K. et al. (2004) Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli. Vaccine 22, 4069-4074, PubMed: 15364458
166. Vazquez, M. et al. (2001) The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 344, 955-960, PubMed: 11274621
167. Tugwell, B.D. et al. (2004) Chickenpox outbreak in a highly vaccinated school population. Pediatrics 113, 455-459, PubMed: 14993534
168. Halloran, M.E. et al. (1994) Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 140, 81-104, PubMed: 8023813
169. Brisson, M. et al. (2000) Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 125, 651-669, PubMed: 11218215
170. Gershon, A.A. et al. (1996) The protective effect of immunologic boosting against zoster: An analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 173, 450-453, PubMed: 8568309
171. Levin, M.J. et al. (2003) Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine. J Infect Dis 188, 1336-1344, PubMed: 14593591
172. Kleymann, G. (2004) Helicase primase: Targeting the Achilles heel of herpes simplex viruses. Antivir Chem Chemother 15, 135-140, PubMed: 15266895
173. Moffat, J.F. et al. (2004) Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis. Biochim Biophys Acta 1697, 225-231, PubMed: 15023363
174. Mo, C. et al. (2002) The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Virology 304, 176-186, PubMed: 12504560
175. Olson, J.K., Bishop, G.A. and Grose, C. (1997) Varicella-zoster virus Fc receptor gE glycoprotein: Serine/threonine and tyrosine phosphorylation of monomeric and dimeric forms. J Virol 71, 110-119, PubMed: 8985329
176. Grose, C. (1990) Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking. Annu Rev Microbiol 44, 59-80, PubMed: 2174668
177. Grose, C. et al. (1984) Varicella-zoster virus-specific gp140: A highly immunogenic and disulfide-linked structural glycoprotein. Virology 132, 138-146, PubMed: 6320530
178. Moffat, J. et al. (2002) Glycoprotein I of varicella-zoster virus is required for viral replication in skin and T cells. J Virol 76, 8468-8471, PubMed: 12134050
179. Cohen, J.I. and Seidel, K.E. (1994) Absence of varicella-zoster virus (VZV) glycoprotein V does not alter growth of VZV in vitro or sensitivity to heparin. J Gen Virol 75 (Pt 11), 3087-3093, PubMed: 7964618
180. Kinchington, P.R. et al. (1990) The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka). J Virol 64, 4540-4548, PubMed: 2166829
181. Forghani, B., Ni, L. and Grose, C. (1994) Neutralization epitope of the varicella-zoster virus gH:gL glycoprotein complex. Virology 199, 458-462, PubMed: 7510086
182. Maresova, L. et al. (2000) Characterization of interaction of gH and gL glycoproteins of varicella-zoster virus: Their processing and trafficking. J Gen Virol 81, 1545-1552, PubMed: 10811938
183. Mo, C. et al. (1999) Characterization of Varicella-Zoster virus glycoprotein K (open reading frame 5) and its role in virus growth. J Virol 73, 4197-4207, PubMed: 10196316
184. Hutchinson, L. et al. (1993) Herpes simplex virus (HSV) glycoproteins B and K inhibit cell fusion induced by HSV syncytial mutants. Virology 196, 514-531, PubMed: 8396800
185. Lehner, R., Meyer, H. and Mach, M. (1989) Identification and characterization of a human cytomegalovirus gene coding for a membrane protein that is conserved among human herpesviruses. J Virol 63, 3792-3800, PubMed: 2547996
186. Cai, J.S. et al. (1999) Identification and structure of the Marek's disease virus serotype 2 glycoprotein M gene: Comparison with glycoprotein M genes of Herpesviridae family. J Vet Med Sci 61, 503-511, PubMed: 10379942
187. Sato, B. et al. (2003) Requirement of varicella-zoster virus immediate-early 4 protein for viral replication. J Virol 77, 12369-12372, PubMed: 14581575
188. Cohen, J.I. and Seidel, K. (1994) Varicella-zoster virus (VZV) open reading frame 10 protein, the homolog of the essential herpes simplex virus protein VP16, is dispensable for VZV replication in vitro. J Virol 68, 7850-7858, PubMed: 7966575
189. Moffat, J.F. et al. (1998) The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc Natl Acad Sci U S A 95, 11969-11974, PubMed: 9751774
190. Besser, J. et al. (2003) Differentiation of varicella-zoster virus ORF47 protein kinase and IE62 protein binding domains and their contributions to replication in human skin xenografts in the SCID-hu mouse. J Virol 77, 5964-5974, PubMed: 12719588
191. Besser, J. et al. (2004) Differential requirement for cell fusion and virion formation in the pathogenesis of varicella-zoster virus infection in skin and T cells. J Virol 78, 13293-13305, PubMed: 15542680
192. Sato, B. et al. (2003) Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo. J Virol 77, 5607-5620, PubMed: 12719553
193. Sommer, M.H. et al. (2001) Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. J Virol 75, 8224-8239, PubMed: 11483768
194. Niizuma, T. et al. (2003) Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model. J Virol 77, 6062-6065, PubMed: 12719598
195. Ito, H. et al. (2003) Promoter sequences of varicella-zoster virus glycoprotein I targeted by cellular transactivating factors determine virulence in skin and T cells in SCIDhu mice in vivo. J Virol 77, 489-498, PubMed: 12477854